261 related articles for article (PubMed ID: 32255214)
1. Tofacitinib cream plus narrowband ultraviolet B phototherapy for segmental vitiligo in a child.
Olamiju B; Craiglow BG
Pediatr Dermatol; 2020 Jul; 37(4):754-755. PubMed ID: 32255214
[TBL] [Abstract][Full Text] [Related]
2. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.
Liu LY; Strassner JP; Refat MA; Harris JE; King BA
J Am Acad Dermatol; 2017 Oct; 77(4):675-682.e1. PubMed ID: 28823882
[TBL] [Abstract][Full Text] [Related]
3. Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation.
Komnitski M; Komnitski A; Komnitski Junior A; Silva de Castro CC
An Bras Dermatol; 2020; 95(4):473-476. PubMed ID: 32418716
[TBL] [Abstract][Full Text] [Related]
4. Rapid Repigmentation of Vitiligo Using Tofacitinib Plus Low-Dose, Narrowband UV-B Phototherapy.
Kim SR; Heaton H; Liu LY; King BA
JAMA Dermatol; 2018 Mar; 154(3):370-371. PubMed ID: 29387870
[No Abstract] [Full Text] [Related]
5. Effectiveness and safety of tofacitinib combined with narrowband ultraviolet B phototherapy for patients with refractory vitiligo in real-world clinical practice.
Song H; Hu Z; Zhang S; Yang L; Liu Y; Wang T
Dermatol Ther; 2022 Nov; 35(11):e15821. PubMed ID: 36114601
[TBL] [Abstract][Full Text] [Related]
6. The use of Janus kinase inhibitors and narrowband ultraviolet BÂ combination therapy in non-segmental vitiligo.
Yousefian F; Yadlapati S; Browning JC
J Cosmet Dermatol; 2023 Mar; 22(3):1105-1107. PubMed ID: 36440703
[TBL] [Abstract][Full Text] [Related]
7. A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo.
McKesey J; Pandya AG
J Am Acad Dermatol; 2019 Aug; 81(2):646-648. PubMed ID: 31009664
[No Abstract] [Full Text] [Related]
8. Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy.
Craiglow BG; King BA
JAMA Dermatol; 2015 Oct; 151(10):1110-2. PubMed ID: 26107994
[TBL] [Abstract][Full Text] [Related]
9. Tetrahydrocurcuminoid cream plus targeted narrowband UVB phototherapy for vitiligo: a preliminary randomized controlled study.
Asawanonda P; Klahan SO
Photomed Laser Surg; 2010 Oct; 28(5):679-84. PubMed ID: 20961233
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of low-dose tofacitinib combining narrowband UVB therapy for treating vitiligo patients who had failed previous therapy: A pilot study.
Fang WC; Chiu SH; Lin SY; Huang SM; Lan CE
Photodermatol Photoimmunol Photomed; 2021 Jul; 37(4):345-347. PubMed ID: 33512041
[No Abstract] [Full Text] [Related]
11. Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and Meta-analysis.
Phan K; Phan S; Shumack S; Gupta M
J Dermatolog Treat; 2022 Feb; 33(1):173-177. PubMed ID: 32096671
[TBL] [Abstract][Full Text] [Related]
12. Narrowband ultraviolet B phototherapy in pediatric vitiligo: A retrospective study.
Garza-Mayers AC; Paquette GM; Harris JE; Wiss K
J Am Acad Dermatol; 2023 Jul; 89(1):135-136. PubMed ID: 36796727
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of tretinoin 0.05% cream to prevent hyperpigmentation during narrowband UV-B phototherapy in patients with facial vitiligo: a randomized clinical trial.
Ju HJ; Kim SH; Lee JH; Kim GM; Bae JM
J Dermatolog Treat; 2022 May; 33(3):1738-1741. PubMed ID: 32869680
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Childhood Vitiligo Using Tacrolimus Ointment with Narrowband Ultraviolet B Phototherapy.
Dayal S; Sahu P; Gupta N
Pediatr Dermatol; 2016 Nov; 33(6):646-651. PubMed ID: 27699846
[TBL] [Abstract][Full Text] [Related]
15. Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology.
Kostovic K; Gulin SJ; Mokos ZB; Ceovic R
Curr Med Chem; 2017 May; 24(11):1158-1167. PubMed ID: 28088907
[TBL] [Abstract][Full Text] [Related]
16. Medical and Maintenance Treatments for Vitiligo.
Passeron T
Dermatol Clin; 2017 Apr; 35(2):163-170. PubMed ID: 28317526
[TBL] [Abstract][Full Text] [Related]
17. Effects of a preceding fractional carbon dioxide laser on the outcome of combined local narrowband ultraviolet B and topical steroids in patients with vitiligo in difficult-to-treat areas.
Vachiramon V; Chaiyabutr C; Rattanaumpawan P; Kanokrungsee S
Lasers Surg Med; 2016 Feb; 48(2):197-202. PubMed ID: 26175036
[TBL] [Abstract][Full Text] [Related]
18. Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo.
Vu M; Heyes C; Robertson SJ; Varigos GA; Ross G
Clin Exp Dermatol; 2017 Dec; 42(8):942-944. PubMed ID: 29034491
[No Abstract] [Full Text] [Related]
19. [Systemic treatment of vitiligo : Balance and current developments].
Meurer M; Ceric-Dehdari P
Hautarzt; 2017 Nov; 68(11):876-884. PubMed ID: 29030646
[TBL] [Abstract][Full Text] [Related]
20. This Month in JAAD International: December 2022: Topical management of vitiligo with Janus kinase inhibitors.
Kantor J
J Am Acad Dermatol; 2022 Dec; 87(6):1284. PubMed ID: 36228949
[No Abstract] [Full Text] [Related]
[Next] [New Search]
